INTRODUCTION
============

Thyroid-like carcinoma of the kidney (TLCK) is microscopically similar to thyroid follicular cell carcinoma (TFCC) and depends on non-reactivity to immunohistochemical (IHC) markers for TFCC (thyroglobulin-TG and TTF1) and on exclusion of other primary renal tumors for diagnosis. We describe a Pediatric case with a literature review.

CLINICAL SCENARIO AND RATIONAL
==============================

Clinical and pathologic findings
--------------------------------

A 10 year-old pre-pubertal female presented with abdominal pain and occasional nausea and vomiting for two months. Her physical examination was normal. An abdominal ultrasound showed an encapsulated 82x69x42mm solid mass with mixed echogenicity, predominantly hyperechoic, in the medium/superior poles of the right kidney. A thoracoabdominal CT confirmed an exophytic, lobulated, solid, circumscribed 63x60x47mm mass in the superior and anterior medium third of the right kidney, with heterogeneous low enhancement after contrast injection. Necrotic and cystic areas were present, abutting but not invading the renal pelvis and hilar vessels. Augmented perihilar and pericaval lymph nodes were present ([Figure-1](#f01){ref-type="fig"}). Her thyroid was functionally normal. No thyroid, ovarian, pelvic, cervical or thoracic tumors were demonstrated.

Figure 1Thyroid-like carcinoma of the kidney. (A) CT with contrast, showing heterogeneous low grade enhancement of the tumor. (B) Well defined tumor showing cystic, hemorrhagic and solid areas. (C) Follicular architecture with microfollicles and macrofollicles filled with colloid-like material.

Right radical nephrectomy and locoregional lymphadenectomy were performed. The kidney mass measured 55x50x50mm and was well encapsulated, showing cystic and solid areas ([Figure-1](#f01){ref-type="fig"}). Microscopically the main feature was the strong resemblance to thyroid tissue. At low magnification the tumor was composed of follicles of variable size. The follicles were lined by cuboidal or flattened epithelial cells and the material in the follicles was eosinophilic. The nuclei were round with uniform distribution of chromatin. Calcification, fibrosis, hemorrhage and necrosis were focally seen. The mass was restricted to the kidney, without vascular, adrenal, renal sinus or lymphatic invasion. The lymph nodes showed no metastases. Immunohistochemistry demonstrated non-reactivity for TTF-1 and thyroglobulin. The tumor cells were also non-immunoreactive with CK20, CD117 and RCC. Other markers were tested with positive results for PAX8, CK7, EMA and vimentin. After 1 year 7 months the patient persists asymptomatic with normal abdominal ultrasounds.

DISCUSSION AND FUTURE PERSPECTIVES
==================================

Twenty-five cases of TLCK have been described. Another 4 are available in Chinese (n=3) and German (n=1). Females predominate (14 females, 6 males, 1 unknown). Ages vary between 19-83 years-old (mean 42.7, median 35). Females tended to be younger (median 32 versus 55 years-old for males). Only 3 other pediatric cases were published (5.3-14 years-old, 2/3 females) (1).

Most cases were asymptomatic, incidentally detected. Approximately 1/5 presented hematuria and/or flank pain. One patient each showed weight loss, anemia and hypertension (cured after resection of a perihilar tumor) ([@B2]). Many tumors were associated with previous malignancy (5/22) or pre-neoplastic conditions ([@B1] case, adult polycystic renal disease).

TLCK predominates in the right kidney (14/22 cases, 63.6%), maximal dimensions varying between 11 and 118mm (mean 44.8mm). Four (18.2%), 11 (50%) and 7 (31.8%) affected the upper, mid and lower poles, respectively.

Most tumors were hyperechoic (contrasting with TFCC, usually hypoechoic) and hyperdense with low grade heterogenous enhancement on CT and MRI. On pre-contrast MRI TLCK showed high signal on T1 and low signal on T2, as compared to the kidney parenchyma ([@B3]). Some presented calcifications. No vascular or urothelial invasion were described, but vessels and renal calices might be displaced. Only two PET scan results are available, both positive to FDG marking ([@B3], [@B4]). Abdominal lymph nodes augmentation most commonly did not correspond to metastasis.

Most patients were treated with radical nephrectomy. Partial nephrectomy was used in 6 cases, apparently with the same results. Three patients presented lung metastases ([@B3], [@B5]). Curiously, in one case the metastatic nodule was immunoreactive to TTF1, as opposed to the kidney specimen ([@B6]). Three adults showed abdominal lymph node metastasis ([@B5], [@B7]).

Follow-up is limited (median 20 months). Most patients did not show progression of the disease or metastases ([Table-1](#t1){ref-type="table"}).

Table 1Summary of clinical characteristics of the tumors described in the literature plus present case.Author/publication yearAge (years)/sexPresentationPast historyLocal/size (mm)ImagingNephrectomy (T/P)/FUAlesssandrini, 2012 ([@B16])76 MHematuriaProstate cancerL UP, 50(CT) Hyperdense, well vascularized, necrotic center, extension to adipose tissue, enlarged lymph nodes (no metastases).T/ 11 months NED41 FIncidentalHodgkin lymphomaR LP, 50(CT) complex cystic, hyperdense no enhancement. (MRI) solid septaP/ 4 months NEDMuscara 2017 ([@B12])27 MIncidental-Left UP, 65-P/8 months NEDAmin 2009 ([@B7])N=6 (29-83), 3M 3 FAll incidental1 Colon cancer, 1 osteosarcoma5R 1L / 1 UP, 4 MP, 2 LP/ 19-40-6 T/ 7-84 months, NEDDawane 2015 ([@B17])49 FIncidental-L MP 24(CT) contrast enhancement, extension to adipose tissue.P/ 5 years, NEDKhoja 2014 ([@B18])31 FHematuria, weight loss, flank pain (3 years), anemiaNormal thyroid (I/F), normal ovaries (I)L UP 43(CT) heterogeneous enhancing, distorting collecting system, lymph node enlargement (no metastases).T/ 21 months NEDJung 2006 ([@B13])32 FIncidentalNormal thyroid (I/F), normal ovaries (I)R LP/ 118(CT) contrast enhancing, hydronephrosis.T/ 6 months NEDDhillon 2011 ([@B5])34 FHematuria, flank painNormal thyroid (I/F)R MP/ 63Multiple pulmonary nodules (biopsy "thyroid carcinoma")"systemic treatment" for thyroid cancer (1 year) + T nephrectomy/ 3 months NEDLin 2014 ([@B8])65 MHematuria (4 years), back pain (1 week)Normal thyroid (I/F)R MP, 80Hypoechogenic hilar mass, (CT) "renal carcinoma", normal fascia/lymph nodes.T/ 2 years NED59 FIncidentalNormal thyroid (I/F)R MP, 60Normal fascia/lymph nodes.T/ 1 month NEDWu 2014 ([@B4])19 FIncidentalLeukemia (5 years-old)R LP 28(CT) heterogeneous hyperdense. No lymph nodes. No metastasis. PET (+).Biopsy + P nephrectomy/ 21 months NED.Wang 2017 ([@B2])25 FSevere hypertension (normal post-operative)Normal thyroid (I/F), normal ovaries (I)R MP 30(CT) inhomogenous enhancement, calcifications. Ovaries normal (imaging).P/ 2 years NED.Ghaouti 2014 ([@B10])68 FIncidentalNormal thyroid (I/F), normal ovaries (I)R MP 11(MRI) Cystic, no enhancementP/ no FU reportedVolavsek 2013 ([@B11])34 ?IncidentalNephrolithiasis,polycystic disease, adult type.L LP 50 mmHyperechogenic cystT/ 6 months NED.Sterlacci 2008 ([@B6])28 FIncidental L MP 44(CT) Heterogeneous, no capsule infiltration, displacement of blood vessels. Left lung nodule.Thyroidectomy (presumed metastatic thyroid cancer, despite normal imaging). Lung lumpectomy. T nephrectomy/ 5 years NED.Vicens 2014 ([@B3])24 FHematuria, flank pain R MP, 60(CT) displaying calices, bilobulated, peripheral calcification, hyperdense, low grade enhancement, peak on delayed phase. Multiple pulmonary nodules, enlarged abdominal lymphonodes. (MRI) increased signal T1, low signal T2, low grade enhancement. PET scan: mild FDG uptake.T/post op therapy with sunitinib for lung metastases. No FU data.Malde 2013 ([@B19])29 FFlank painThyroid normal (F)L LP, 58(CT) Complex multiseptated partially cystic, low attenuation, no enhancement. (MRI) no enhancement.T. No FU data.Our case10 FFlank pain, nausea, vomitingThyroid (I/F) and ovaries I) normalR +SP/MP, 63US hyperchoic heterogeneous, CT exophytic anterior superior/medium pole, heterogeneous enhancement, necrotic and cystic areas, lymph node enhancement (no metastases)T. NED, normal imaging after 19 months.[^2]

Differential diagnosis depends on IHC profile. The diseases to be considered are:

1.Malignancies:
---------------

a.  Renal metastasis from TFCC from normal or ectopic thyroid tissue (possible on the neck and/or thorax, mainly in the vicinity of the thyroid gland, but not in kidney tissue (6)). Less than 40 cases were described ([@B4]), generally associated with widespread metastatic disease (mostly to the lungs, lymph nodes and bones). The metastases are positive to TTF1/TG. A primary tumor should be detectable.

b.  Metastasis from struma ovarii (2% of the ovarian tumors, malignant in 5-10% of the cases). Metastases are rare (5%), preferentially to the liver and peritoneum, and positive to TTF1/TG ([@B6]).

c.  Papillary renal cell carcinoma may show patchy "thyroid-like" areas, but the typical architecture usually predominates. IHC is positive to kidney tumor markers.

d.  Renal carcinoids may show zonal "follicular" architecture, positive to neuroendocrine markers (synaptophysin, CD 56 and chromogranin). Oncocytomas and metanephric adenomas may also show focal or patchy "follicular" architecture, due to eosinophilic intraluminal deposits in areas of tubular differentiation.

2.Benign entities:
------------------

a.  Kidney "thyreodization" associated to end-stage kidney disease/pyelonephritis, caused by the deposit of colloid-like protein material in the lumina of atrophic distal tubules/collecting ducts. This is a diffuse and bilateral process, not associated with tumors.

TLCK are well circumscribed, yellow/whitish. Hemorrhagic and necrotic areas are common and may present as intratumoral "cysts" ([@B2], [@B8], [@B9]). Histologically there are macro and microfollicles filled with amorphous eosinophilic colloid-like material ([@B5], [@B10]), similar to TFCC. The follicles are lined with cuboidal cells with scant eosinophilic cytoplasm, round/oval nuclei and evenly distributed chromatin. Mitotic activity is absent or scarce. There may be focal areas of papillary differentiation, patchy lymphoid aggregates, calcifications ([@B2], [@B3], [@B10]-[@B12]) and cholesterol crystals ([@B12]). Fibrous septa presenting muscle and a fibrous pseudocapsule have been described ([@B7], [@B12]). No cases presented with vascular or collecting system invasion. Capsular invasion was seen in two cases ([@B11]).

The tumor is, by definition, negative to TG/TTF1, positive to epithelial markers (cytokeratyns AE1/AE3, 7, PAX 2 and 8, Vimentin and EMA) and negative to renal tumor markers (WT1, RCC, CD10).

TLCK was described in 2006 ([@B13]), is an emerging entity and has not yet been included in the WHO classification of tumors ([@B14]). A possible previous case was positive for thyroid IHC markers ([@B15]) and is questionable. The predominance of young women suggests some hormonal influence and the relatively high incidence of previous malignancies suggests that previous treatments and/or specific genetic constitutions predispose to TLCK.

Extra-renal extra-thyroid tumors (cholangiocarcinoma, breast and urothelial carcinomas, endolymphatic sac tumor, plasmacytoma, papillary renal cell carcinoma) may also present "follicular" architecture and are negative for TG and TTF1 ([@B4], [@B7], [@B16]). Tubular deposits of Tamm-Horsfall glicoprotein are probably the explanation for the colloidal aspect in kidney tumors, including TLCK ([@B5], [@B10]).

Primary thyroid tumors are positive to TTF1/TG, except for poorly differentiated or sarcoma-like malignancies. For kidney tumors, the IHC panel includes vimentin, CK 7, AMACR, CCR and CD10 and WT1 in atypical tumors or children. A "thyroid tumor" on a kidney specimen is unexpected and at least one patient was, quite understandably, submitted to a thyroidectomy with the presumed diagnosis of metastatic TFCC, despite normal thyroid imaging ([@B6]). Non-reactivity to TG/TTF1 and no primary tumor are the clues to avoid this. [Table-2](#t2){ref-type="table"} summarizes the IHC profiles and differential diagnosis for TFCC, kidney tumors and TLCK.

Table 2IHC characteristics of TLCK, other kidney tumors and thyroid tumor.TumorPositiveNegativeRCC (Clear cell)VimentinHMWCKAE1/AE3CK7, CK20RCCMe-cadherin,PAX2/PAX8CD117AMACRRCC (papillary)VimentinCD117AE1/AE3CK7AMACRRCCMPAX2/PAX8Chromophobe RCC/oncocytomae-cadherinVimentinCD117AMACRAE1/AE3CK7 (Chromophobe)WTCD 57 (tubules (+), blastema (-)CK7CK22, CK18, CK8MyoglobinEMAChromogranin AactinRCCWT1P53desminVimentin - blastema, focally (+)TFCCPAX 8PAX 2TTF1, TG, BME1, galactin 3 TLCKCK 7, AE1/3TTF1, TGPAX 2, 8WT1VimentinRCCEMACD10CEAp53

Surgical resection with clear margins is probably curative, despite the limitations of follow-up data. Partial nephrectomy seems to be as successful as total nephrectomy, but the high proportion of mid pole tumors may impose technical difficulties. Metastases are rare and apparently do not compromise the results in most patients. Adjuvant therapy has not been established.
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